UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 11, 2015
AKERS
BIOSCIENCES, INC.
(Exact
name of registrant as specified in its charter)
New Jersey |
|
333-190456 |
|
22-2983783 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification
No.) |
201
Grove Road
Thorofare,
NJ 080086
(Address
of Principal Executive Offices)
(856)
848-2116
Registrant’s
telephone number, including area code
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
Appointment
of Director
On
November 11, 2015, at a special meeting of the Board of Directors of the Company (the “Board”), the Board appointed
Dr. Raza Bokhari as director of the Company, effective immediately.
Dr.
Raza Bokhari, age 48
Dr.
Raza Bokhari, age 48, has over 24 years of experience in healthcare senior management. Previously, he has been involved in five
companies, also in the healthcare sector, holding positions including Chairman, Chief Executive Officer (CEO), President and Chief
Development Officer (CDO). From Jan 2001 through May 2007, Dr. Bokhari was President and CEO of Lakewood Pathology Associates
Inc., a national provider of anatomic pathology and diagnostic services company. From April 2003 to May 2008, he was the President
and CEO of Parkway Clinical Laboratories (PCL), a national clinical reference laboratory with a focus on serving pain management
specialists, behavioral health providers, and anti-aging and wellness providers. Dr. Bokhari again joined PCL in May 2013 to present
day and serves as the Chairman and CEO. From May 2008 to May 2009, Dr. Bokhari was the Chief Development officer of Rosetta Genomics
(ROSG) a publicly traded, microRNA-based diagnostic testing company. He also serves as Vice Chairman of the World Affairs Council
of Philadelphia and is a Trustee of the esteemed Foreign Policy Research Institute. He has previously served as Trustee of Franklin
Institute. Dr. Bokhari has a Doctor of Medicine degree from University of Punjab, Rawalpindi Medical College, Pakistan and an
Executive MBA from the Fox School of Business, Temple University in Philadelphia, PA.
In
evaluating Dr. Bokhari’s experience, qualifications, attributes and skills in connection with his appointment to the Board,
the Company took into account his extensive experience in the healthcare and medical diagnostic industries.
Family
Relationships
Dr.
Bokhari does not have any family relationships with a current officer or director of the Company.
Related
Party Transactions
There
are no related party transactions.
Item
9.01 Financial Statements and Exhibits.
(c)
Exhibits
Exhibit
No. |
|
Description |
|
|
|
99.1* |
|
Press
Release |
*filed
herewith
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AKERS
BIOSCIENCES, INC. |
|
|
|
Date:
November 16, 2015 |
By: |
/s/
Raymond F. Akers, Jr., PhD |
|
|
Raymond
F. Akers, Jr., PhD |
|
|
Executive
Chairman |
Akers
Biosciences Appoints Dr. Raza Bokhari as Non-executive Director
THOROFARE,
N.J., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ:AKER) (AIM:AKR.L), (the “Company”), a medical
device company focused on reducing the cost of healthcare through faster, easier diagnostics, is pleased to announce the appointment
of Raza Bokhari M.D. as a Non-executive Director of the Company.
Dr.
Bokhari has significant experience of working with life science and healthcare services companies in the US. He currently serves
as the Managing Partner of RBx Capital LP, a private equity fund in formation focused on investing in all segments of the US laboratory
testing market. Dr. Bokhari is also Chairman and CEO of Parkway Clinical Laboratories, a College of American Pathologists accredited
national CLIA-certified clinical reference laboratory performing diagnostic testing procedures.
In
2001, Dr. Bokhari acquired Lakewood Pathology Associates. During his term as President and CEO, until 2007, Lakewood Pathology
Associates grew revenues ten times, expanded its client base to 25 states and created over 100 new jobs in the South Jersey region.
It was sold in 2006 to Chicago-based private equity fund, Water Street Healthcare Partners, and received a $50 million equity
commitment.
Dr.
Bokhari has a Doctor of Medicine degree from the University of Punjab, Rawalpindi Medical College, Pakistan, and an Executive
MBA from The Fox School of Business at Temple University, PA, where he now serves as Chairman of the Executive Advisory Committee.
Dr. Bokhari is frequently retained as a consultant for due diligence by private equity and venture capital funds focused on investing
in life science, biotechnology and healthcare services companies.
“Dr.
Bokhari is a very highly respected individual within the US healthcare business community,” said Raymond F. Akers, Jr. PhD,
Co-founder and Executive Chairman. “We are delighted to welcome him to the board of Akers Bio. His expertise, particularly
in the fields of laboratory testing and health and wellness diagnostics - a growing area of importance for Akers Bio - will be
invaluable as we continue to accelerate the commercialization of the Company’s rapid diagnostic assays,” added Dr.
Akers.
About
Akers Biosciences, Inc.
Akers
Biosciences develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective
healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding
to major shifts in healthcare through the development of several proprietary platform technologies. The Company’s state-of-the-art
rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with
major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide
competitor in diagnostics.
Additional
information on the Company and its products can be found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary
Statement Regarding Forward Looking Statements
Statements
contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
Such forward-looking statements reflect the Company’s expectations about its future operating results, performance and opportunities
that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended
terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words “anticipate,”
“believe,” “estimate,” “upcoming,” “plan,” “target”, “intend”
and “expect” and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management,
are intended to identify such forward-looking statements. These forward-looking statements are based on information currently
available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company’s
actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking
statements.
CONTACT:
For more information:
Akers
Biosciences, Inc.
Raymond
F. Akers, Jr. PhD
Executive
Chairman of the Board
Tel.
+1 856 848 8698
Taglich
Brothers, Inc. (Investor Relations)
Chris
Schreiber
Tel.
+1 917 445 6207
cs@taglichbrothers.com
finnCap
(UK Nominated Adviser and Broker)
Adrian
Hargrave / Scott Mathieson (Corporate Finance)
Steve
Norcross (Broking)
Tel.
+44 (0)20 7220 0500
Vigo
Communications (Public Relations)
Ben
Simons / Fiona Henson
Tel.
+44 (0)20 7016 9570
akers@vigocomms.com
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Jun 2024 to Jul 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Jul 2023 to Jul 2024